Digg It
#1 in Business Subscribe Email Print

You are here: Home > Business > Management > The Blind Men and the Elephant

Tags

  • packaged
  • understanding
  • product
  • biological product
  • companies involved

  • Links

  • Horse Racing Systems: The Key Factors For Success
  • How to Plan Your Retirement Abroad
  • Leads Generation- Get The Leads You Want With Traffic Exchanges
  • Digg It - The Blind Men and the Elephant

    The Blind Men and the Elephant

    It was six men of Indostan
    To learning much inclined,
    Who went to see the Elephant
    (Though all of them were blind),
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    That each by observation
    Might satisfy his mind.

    The First approached the Elephant,
    And happening to fall
    Against his broad and sturdy side,
    At
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    once began to bawl:
    “God bless me! But the Elephant
    Is very like a wall!”

    The Second feeling the tusk,
    Cried, “Ho, what have we here,
    So very ro
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    nd and smooth and sharp?
    To me ‘tis mighty clear
    This wonder of an Elephant
    Is very like a spear!”

    The Third approached the animal,
    And happening
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    to take
    The squirming trunk within his hands,
    Thus boldly up and spake:
    “I see,” quoth he, “the Elephant
    Is very like a snake!”

    The Fourth reach
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    ed out an eager hand,
    And felt about the knee.
    “What most this wondrous beast is like
    Is mighty plain,” quoth he;
    “’Tis clear enough the Elephant<
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    r> Is very like a tree!”

    The Fifth, who chanced to touch the ear,
    Said: “E’en the blindest man
    Can tell what this resembles most;
    Deny the fact who c
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    an,
    This marvel of an Elephant
    Is very like a fan!”

    The Sixth no sooner had begun
    About the beast to grope,
    Than, seizing on the swinging tail
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    > That fell within his scope,
    “I see,” quoth he, “the Elephant
    Is very like a rope!”

    And so these men of Indostan
    Disputed loud and long,
    Each i
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    his own opinion
    Exceeding stiff and strong,
    Though each was partly in the right,
    And all were in the wrong!

    John Godfrey Saxe (1816-1887)

    Well you a
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    re now probably wondering whether you have signed up for a poetry course or one about management and management planning. Replace each of these wonderful men of Indos
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    tan with a member of your team. As a way of explanation let’s look at a management team made up of the CEO, CFO, CTO and all the other C’s. Each comes to the table wi
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    h many years of experience and study behind them. They come with a thorough understanding of their role in the company but a limited understanding of the other C’s ro
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    les.

    Now imagine your revenue is on a downward trend and you have come together to try and reverse this trend. Each member will see the problem and solution from the
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    ir own familiar position. You will sit around and argue long and hard about how to tackle this problem. If each took a tour of the ‘elephant’ and tried to understand
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    ach part and how each part makes the whole then it might become clear that the elephant has a thorn in his foot and therefore can’t walk to get his food and water and
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    so is becoming malnourished.

    Understanding each part of the elephant and how they come together to make the whole is what Peter Senge calls ‘systems thinking’ and i
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    s one of the five disciplines that make a learning organization.

    We are not saying that the CFO needs to go and get a marketing degree and work in marketing. But if
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    ach member of the team listens and tries to understand the whole ‘elephant’ rather than stating their position more and more firmly, then the team has more chance of
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    reaching a true understanding. The team has more chance of fixing the problem and achieving success.

    Open your eyes and see the whole ‘elephant’ for what it truly is


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.diggit.org.ua/article/23399/diggit-The-Blind-Men-and-the-Elephant.html">The Blind Men and the Elephant</a>

    BB link (for phorums):
    [url=http://www.diggit.org.ua/article/23399/diggit-The-Blind-Men-and-the-Elephant.html]The Blind Men and the Elephant[/url]

    Related Articles:

    Slip Sheets Explained

    Pay Structure

    Expanding Your Income Stream

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com